Related references
Note: Only part of the references are listed.Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer
Neal D. Shore et al.
FUTURE ONCOLOGY (2022)
Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.
Michael Cookson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D. Shore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin
Nelleke Snelder et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer
Bruno Nascimento et al.
JOURNAL OF SEXUAL MEDICINE (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
An automated sampling importance resampling procedure for estimating parameter uncertainty
Anne-Gaelle Dosne et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
C. Brooke Steele et al.
CANCER (2017)
A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
Alessandro Sciarra et al.
MEDICINE (2016)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking et al.
CLINICAL PHARMACOKINETICS (2015)
Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
Laurence Klotz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The hypothalamo-pituitary-gonadal axis
Tony M. Plant
JOURNAL OF ENDOCRINOLOGY (2015)
Testosterone Treatment Is a Potent Tumor Promoter for the Rat Prostate
Maarten C. Bosland
ENDOCRINOLOGY (2014)
Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance
W. Byon et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Tom Pickles et al.
BJU INTERNATIONAL (2012)
Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of Triptorelin Administered in Sustained Release Formulations in Patients with Prostate Cancer
Elba Romero et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare?
William K. Oh et al.
UROLOGY (2010)
Handling Data Below the Limit of Quantification in Mixed Effect Models
Martin Bergstrand et al.
AAPS JOURNAL (2009)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
Juan Morote et al.
BJU INTERNATIONAL (2009)
ABCB1 genotype and PGP expression, function and therapeutic drug response:: a critical review and recommendations for future research
G. D. Leschziner et al.
PHARMACOGENOMICS JOURNAL (2007)
Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues
Christoffer W. Tornoe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer
V Murthy et al.
BJU INTERNATIONAL (2006)
Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer
H Kaku et al.
PROSTATE (2006)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
JW Moul et al.
JOURNAL OF UROLOGY (2004)
Hormonal therapy: Historical perspective to future directions
DG McLeod
UROLOGY (2003)
Share Paper
